Porous Fe/Cu Nanoreactor with Dual Insurance Design for Precision Chemotherapy and Chemodynamic Therapy
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202405229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Xianyu Zhu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Precision and Intelligence Medical Imaging Lab, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Rd., Xicheng Dist., Beijing, 1000…. Hauptthemen laut MEDLINE: Copper, Iron, Antineoplastic Agents, Metal Nanoparticles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, CAMS Innovation Fund for Medical Sciences, Beijing Friendship Hospital, Capital Medical University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Poor prognosis and chemotherapy response stem from difficulties in precise targeting and the lack of effective synergistic treatments. Nanozymes show promising potential in tumor chemodynamic therapy (CDT) by catalyzing hydrogen peroxide (H₂O₂) decomposition and glutathione depletion in the tumor microenvironment (TME). However, integrating precise chemotherapy targeting with CDT remains challenging. In this study, a porous Fe/Cu bimetallic nanozyme carrier (FeCuNPs) is developed for co‐loading with the humanized 3F8 anti‐GD2 disialoganglioside antibody (3F8) and the novel pyridazinone‐based chemotherapeutic agent (IMB), forming a nanoreactor (3F8@FeCuNPs@IMB) for targeted chemotherapy and CDT. The nanoreactor responds specifically to the acidic TME as a primary insurance, allowing for the controlled release of IMB at the tumor site. The targeting antibody 3F8 coating on the surface of the nanozyme carrier acts as a secondary insurance, minimizing chemotherapy drug leakage during the delivery process and ensuring precise targeting for effective chemotherapy. Furthermore, FeCuNPs act as peroxidase‐like (POD) and glutathione oxidase‐like (GSHOX) enzymes, catalyzing hydroxyl radical (•OH) generation and depleting excess GSH, enhancing CDT. The results in vitro and in vivo indicate that the dual insurance designed 3F8@FeCuNPs@IMB offers a promising prospect for a targeted, precise, and effective combination of chemotherapy and CDT against melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision and Intelligence Medical Imaging Lab, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Rd., Xicheng Dist., Beijing, 100050, China.
- Beijing Clinical Research Institute, 95 Yong'an Rd., Xicheng Dist., Beijing, 100050, China.
- Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Tiantan Xili No. 1, Beijing, 100050, China.
ORCID-Profile: Xianyu Zhu
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- CAMS Innovation Fund for Medical Sciences
- Beijing Friendship Hospital, Capital Medical University
Zitieren
APA
Zhu, X., Gao, L., Zheng, Y., Zhao, P. F., Wei, H., Liu, R., Zhao, L., Zhang, J., Sun, Q., Zheng, L., Lv, H., Yang, J., Gong, J., & Wang, Z. (2025). Porous Fe/Cu Nanoreactor with Dual Insurance Design for Precision Chemotherapy and Chemodynamic Therapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202405229
Vancouver
Zhu X, Gao L, Zheng Y, Zhao PF, Wei H, Liu R, et al. Porous Fe/Cu Nanoreactor with Dual Insurance Design for Precision Chemotherapy and Chemodynamic Therapy. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202405229
BibTeX
@article{Zhu2025,
author = {Zhu, Xianyu and Gao, Lingli and Zheng, Yanbo and Zhao, Peng Fei and Wei, Hanrui and Liu, Ruixue and Zhao, Liping and Zhang, Junyi and Sun, Qi and Zheng, Lingling and Lv, Han and Yang, JiGang and Gong, Jianhua and Wang, Zhenchang},
title = {Porous Fe/Cu Nanoreactor with Dual Insurance Design for Precision Chemotherapy and Chemodynamic Therapy},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202405229}
}
EUVIMED